Though meningococcal conjugate vaccines are effective against serogroup C, there is currently no vaccine solution for serogroup B disease. PorA outer membrane protein (OMP) is a potential serogroup B vaccine candidate. A hexavalent PorA outer membrane vesicle (OMV) vaccine has been evaluated in phase I and II trials with promising results. However, considerable sequence variation occurs in the variable regions (VRs) encoding these serosubtypes. By using five wild type P1.19,15 variant strains we examined the serum bactericidal antibody (SBA) titres from sera collected from toddlers and school children pre- and post-vaccination. The numbers of subjects with SBA titres of <4, 4 and > or = 8 varied greatly between the different strains. This was also reflected when > or = 4-fold rises in SBA titres were examined. This finding in sera from toddlers and school children may have implications for PorA based vaccines.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2004.11.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Limited protective immunologic responses to natural infection and a lack of knowledge about mechanisms of protection have hampered development of an effective vaccine. Recent studies in humans and mice have found meningococcal outer membrane vesicle-containing vaccines (OMV) induce cross species immune responses against gonococci and are associated with protection. The exact mechanisms or how humoral and cellular immunity are related to protection, remain unclear.
View Article and Find Full Text PDFCampycins are novel broad-spectrum antibacterials killing Campylobacter jejuni.
Appl Microbiol Biotechnol
October 2024
Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark.
Article Synopsis
- Pyocins are large antibacterial proteins from Pseudomonas aeruginosa that can be modified to target different bacteria, leading to the creation of campycins aimed at killing Campylobacter jejuni, a major foodborne pathogen.
- Two distinct receptor binding proteins from prophages in C. jejuni were used to develop campycins 1 and 2, which effectively eliminate all tested strains of C. jejuni under specific conditions.
- Both campycins bind to the major outer membrane protein (MOMP) of C. jejuni in a strain-specific manner, suggesting their potential for widespread application against various strains of this pathogen in both agricultural and human health contexts.
Bactericidal Antibody Responses to Meningococcal Recombinant Outer Membrane Proteins.
J Microbiol Biotechnol
July 2024
Department of Pediatrics, Shandong Provincial Third Hospital, Shandong University, No.11 Wuyingshan, Middle Road, Tianqiao District, Jinan, Shandong 250031, P.R. China.
Secretin PilQ is an antigenically conserved outer membrane protein that is present in most meningococci and PorA is a major protein that elicits bactericidal immune response in humans following natural disease and immunization. In the present study, BALB/c mice were immunized subcutaneously with rPilQ406-770 or rPorA together with Freund's adjuvant (FA). Serum antibody responses to serogroup A and B whole cells or purified proteins and functional activity of antibodies were determined by ELISA and serum bactericidal assay (SBA), respectively.
View Article and Find Full Text PDFA Fluorinated Sialic Acid Vaccine Lead Against Meningitis B and C.
J Am Chem Soc
June 2024
Institute for Organic Chemistry, University of Münster, Corrensstraße 36, Münster 48149, Germany.
Inspired by the specificity of α-(2,9)-sialyl epitopes in bacterial capsular polysaccharides (CPS), a doubly fluorinated disaccharide has been validated as a vaccine lead against serogroups C and/or B. Emulating the importance of fluorine in drug discovery, this molecular editing approach serves a multitude of purposes, which range from controlling α-selective chemical sialylation to mitigating competing elimination. Conjugation of the disialoside with two carrier proteins (CRM197 and PorA) enabled a semisynthetic vaccine to be generated; this was then investigated in six groups of six mice.
View Article and Find Full Text PDFRecurrent Campylobacter jejuni Infections with Selection of Resistance to Macrolides and Carbapenems: Molecular Characterization of Resistance Determinants.
Microbiol Spectr
August 2023
French National Reference Centre for Campylobacters and Helicobacters, Bordeaux Hospital University Centre, Bordeaux, France.
We present two independent cases of recurrent multidrug-resistant Campylobacter jejuni infection in immunocompromised hosts and the clinical challenges encountered due to the development of high-level carbapenem resistance. The mechanisms associated with this unusual resistance for were characterized. Initial macrolide and carbapenem-susceptible strains acquired resistance to erythromycin (MIC > 256mg/L), ertapenem (MIC > 32mg/L), and meropenem (MIC > 32mg/L) during treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!